Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance

Autores
Presa, Jessica Lorena; Pomilio, Carlos Javier; Vinuesa, María Angeles; Bentivegna, Melisa Inés María; Alaimo, Agustina; Gregosa Merlino, Amal Patricio; Beauquis, Juan; Kwang, Sik Kim; Rabinovich, Gabriel Adrián; Saravia, Flavia Eugenia
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.
Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Kwang, Sik Kim. University Johns Hopkins; Estados Unidos
Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience
Daegu
Corea del Sur
International Brain Research Organization
Korea Brain Research Institute
The Korean Society for Brain and Neural Sciences
Materia
Alzheimer
Blood-brain-barrier
Microglia
Galectin-1
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/130220

id CONICETDig_b432060f02f655c7a7bfd170934d490a
oai_identifier_str oai:ri.conicet.gov.ar:11336/130220
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearancePresa, Jessica LorenaPomilio, Carlos JavierVinuesa, María AngelesBentivegna, Melisa Inés MaríaAlaimo, AgustinaGregosa Merlino, Amal PatricioBeauquis, JuanKwang, Sik KimRabinovich, Gabriel AdriánSaravia, Flavia EugeniaAlzheimerBlood-brain-barrierMicrogliaGalectin-1https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Kwang, Sik Kim. University Johns Hopkins; Estados UnidosFil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaThe 10th International Brain Research Organization (IBRO) World Congress of NeuroscienceDaeguCorea del SurInternational Brain Research OrganizationKorea Brain Research InstituteThe Korean Society for Brain and Neural SciencesElsevier2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectCongresoJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/130220Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S4772451-8301CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2451830119315547info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ibror.2019.07.1502Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:36:04Zoai:ri.conicet.gov.ar:11336/130220instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:36:05.29CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
title Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
spellingShingle Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
Presa, Jessica Lorena
Alzheimer
Blood-brain-barrier
Microglia
Galectin-1
title_short Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
title_full Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
title_fullStr Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
title_full_unstemmed Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
title_sort Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
dc.creator.none.fl_str_mv Presa, Jessica Lorena
Pomilio, Carlos Javier
Vinuesa, María Angeles
Bentivegna, Melisa Inés María
Alaimo, Agustina
Gregosa Merlino, Amal Patricio
Beauquis, Juan
Kwang, Sik Kim
Rabinovich, Gabriel Adrián
Saravia, Flavia Eugenia
author Presa, Jessica Lorena
author_facet Presa, Jessica Lorena
Pomilio, Carlos Javier
Vinuesa, María Angeles
Bentivegna, Melisa Inés María
Alaimo, Agustina
Gregosa Merlino, Amal Patricio
Beauquis, Juan
Kwang, Sik Kim
Rabinovich, Gabriel Adrián
Saravia, Flavia Eugenia
author_role author
author2 Pomilio, Carlos Javier
Vinuesa, María Angeles
Bentivegna, Melisa Inés María
Alaimo, Agustina
Gregosa Merlino, Amal Patricio
Beauquis, Juan
Kwang, Sik Kim
Rabinovich, Gabriel Adrián
Saravia, Flavia Eugenia
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Alzheimer
Blood-brain-barrier
Microglia
Galectin-1
topic Alzheimer
Blood-brain-barrier
Microglia
Galectin-1
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.
Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Kwang, Sik Kim. University Johns Hopkins; Estados Unidos
Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience
Daegu
Corea del Sur
International Brain Research Organization
Korea Brain Research Institute
The Korean Society for Brain and Neural Sciences
description Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Congreso
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/130220
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S477
2451-8301
CONICET Digital
CONICET
url http://hdl.handle.net/11336/130220
identifier_str_mv Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S477
2451-8301
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2451830119315547
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ibror.2019.07.1502
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614380581289984
score 13.070432